showard	10.1200/JCO.2017.35.15_suppl.e18025	<http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18025>; rel="canonical"	<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:j.0="http://purl.org/dc/terms/" xmlns:j.1="http://prismstandard.org/namespaces/basic/2.1/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:j.2="http://purl.org/ontology/bibo/" xmlns:j.3="http://xmlns.com/foaf/0.1/"><rdf:Description rdf:about="http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.e18025"><j.0:isPartOf><j.2:Journal rdf:about="http://id.crossref.org/issn/0732-183X"><j.1:issn>1527-7755</j.1:issn><j.2:issn>1527-7755</j.2:issn><owl:sameAs>urn:issn:1527-7755</owl:sameAs><owl:sameAs>urn:issn:0732-183X</owl:sameAs><j.0:title>Journal of Clinical Oncology</j.0:title><j.1:issn>0732-183X</j.1:issn><j.2:issn>0732-183X</j.2:issn></j.2:Journal></j.0:isPartOf><j.2:volume>35</j.2:volume><j.0:publisher>American Society of Clinical Oncology (ASCO)</j.0:publisher><owl:sameAs rdf:resource="http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18025"/><j.1:endingPage>e18025</j.1:endingPage><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/scott-c-howard-hmk5h3ylc50n"><j.3:name>Scott C. Howard</j.3:name><j.3:familyName>Howard</j.3:familyName><j.3:givenName>Scott C.</j.3:givenName></j.3:Person></j.0:creator><owl:sameAs rdf:resource="info:doi/10.1200/jco.2017.35.15_suppl.e18025"/><j.0:identifier>10.1200/jco.2017.35.15_suppl.e18025</j.0:identifier><j.1:startingPage>e18025</j.1:startingPage><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/timothy-joseph-yeatman-hmk5h3ylc50n"><j.3:name>Timothy Joseph Yeatman</j.3:name><j.3:familyName>Yeatman</j.3:familyName><j.3:givenName>Timothy Joseph</j.3:givenName></j.3:Person></j.0:creator><j.2:doi>10.1200/jco.2017.35.15_suppl.e18025</j.2:doi><j.2:pageEnd>e18025</j.2:pageEnd><j.0:date rdf:datatype="http://www.w3.org/2001/XMLSchema#date" >2017-05-20</j.0:date><j.1:volume>35</j.1:volume><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/mark-layton-watson-hmk5h3ylc50n"><j.3:name>Mark Layton Watson</j.3:name><j.3:familyName>Watson</j.3:familyName><j.3:givenName>Mark Layton</j.3:givenName></j.3:Person></j.0:creator><j.0:creator><j.3:Person rdf:about="http://id.crossref.org/contributor/catherine-lam-hmk5h3ylc50n"><j.3:name>Catherine Lam</j.3:name><j.3:familyName>Lam</j.3:familyName><j.3:givenName>Catherine</j.3:givenName></j.3:Person></j.0:creator><j.2:pageStart>e18025</j.2:pageStart><j.0:title>Increasing the duration and efficacy of intravenous chemotherapy using a patient-centered digital education program: Navigating Cancerâ€™s program for patients receiving pemetrexed for lung cancer.</j.0:title><j.1:doi>10.1200/jco.2017.35.15_suppl.e18025</j.1:doi><owl:sameAs rdf:resource="doi:10.1200/jco.2017.35.15_suppl.e18025"/></rdf:Description></rdf:RDF>
